Ingelvac CircoFLEX


inactivated porcine circovirus vaccine

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Ingelvac CircoFLEX.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Ingelvac CircoFLEX.

For practical information about using Ingelvac CircoFLEX, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 18/10/2021

Authorisation details

Product details
Ingelvac CircoFLEX
Agency product number
Active substance
porcine circovirus type 2 ORF2 protein
International non-proprietary name (INN) or common name
inactivated porcine circovirus vaccine
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Boehringer Ingelheim Vetmedica GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address

D-55216 Ingelheim am Rhein

Product information

15/07/2021 Ingelvac CircoFLEX - EMEA/V/C/000126 - WS/1921

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunologicals for suidae

Therapeutic indication

For active immunisation of pigs over the age of two weeks against porcine circovirus type 2 (PCV2) to reduce mortality, clinical signs - including weight loss - and lesions in lymphoid tissues associated with PCV2-related disease (PCVD).

In addition, vaccination has been shown to reduce PCV2 nasal shedding, viral load in blood and lymphoid tissues, and duration of viraemia.

Onset of protection occurs as early as two weeks post vaccination and lasts for at least 17 weeks.

Assessment history


How useful was this page?

Add your rating
1 rating